

Appendix: Tables

1.	Sales January to March 2026 and 2025	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2026 and 2025	3
3.	Product sales Pharmaceuticals Division and constant exchange rate growth Q1 2026 vs. Q1 2025.....	4
4.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth.....	6
5.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States	7
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe.....	8
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan.....	9
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International	10

1. Sales January to March 2026 and 2025

CHF millions	Three months ended 31 March		% change	
	2026	2025	At CER	In CHF
Pharmaceuticals Division	11,469	11,949	7	-4
United States	5,693	6,224	5	-9
Europe	2,234	2,320	-1	-4
Japan	649	671	14	-3
International	2,893	2,734	16	6
Diagnostics Division	3,253	3,491	3	-7
Roche Group	14,722	15,440	6	-5

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

2. Quarterly sales and constant exchange rate sales growth by Division in 2026 and 2025

CHF millions	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025
Pharmaceuticals Div.	11,949	8	12,036	11	11,570	7	12,114	9	11,469	7
United States	6,224	6	6,446	13	6,128	5	6,557	9	5,693	5
Europe	2,320	5	2,246	5	2,252	5	2,346	7	2,234	-1
Japan	671	3	754	7	714	6	743	4	649	14
International	2,734	18	2,590	11	2,476	11	2,468	16	2,893	16
Diagnostics Division	3,491	0	3,468	0	3,348	2	3,540	6	3,253	3
Roche Group	15,440	6	15,504	8	14,918	6	15,654	8	14,722	6

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

3. Product sales Pharmaceuticals Division and constant exchange rate growth Q1 2026 vs. Q1 2025

CHF millions	Total		United States		Europe		Japan		International	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	1,692	6	1,117	3	363	9	-	-	212	24
Hemlibra	1,190	13	613	15	252	5	81	18	244	14
Vabysmo	1,024	13	652	4	190	0	37	39	145	126
Tecentriq	811	4	378	6	202	-6	69	0	162	14
Xolair	708	26	708	26	-	-	-	-	-	-
Phesgo	686	27	159	2	206	7	42	23	279	78
Perjeta	672	-11	263	-12	119	-15	12	-19	278	-9
Actemra/RoActemra	534	-4	248	-3	124	-16	66	9	96	5
Evrysdi	464	19	160	15	159	13	18	4	127	40
Kadcyla	439	-4	156	-11	123	-6	19	6	141	5
Polivy	407	26	171	26	63	-32	46	24	127	120
Alecensa	401	12	105	-7	63	-5	43	4	190	39
MabThera/Rituxan	292	10	183	16	31	-8	3	-6	75	6
Activase/TNKase	255	-2	244	-2	-	-	-	-	11	-4
Gazyva	247	10	115	1	57	-2	9	28	66	45
Herceptin	234	-12	44	-16	69	-7	1	-24	120	-14
Avastin	224	-9	59	-15	14	3	21	-29	130	-1
CellCept	99	10	4	-5	28	-14	9	-16	58	37
Enspryng	96	31	22	20	11	20	35	13	28	93
Columvi	95	77	43	35	21	84	-	-	31	204
Elevidys	61	54	-	-	-	-	3	-	58	46
Itovebi	52	307	36	183	4	*	-	-	12	-
Rozlytrek	39	6	7	-43	6	18	1	-12	25	38

Lunsumio	37	101	24	95	4	-24	6	*	3	465
Luxturna	20	-33	20	-33	-	-	-	-	-	-
Xofluza	19	-86	7	-41	1	*	-	-	11	-91
PiaSky	14	88	-	-	3	246	11	72	-	-100
Cotellic	11	-5	5	-8	2	-13	-	-	4	4
Susvimo	4	138	4	138	-	-	-	-	-	-
Pharma other	642	-5	146	-28	119	4	117	31	260	-4
Pharma total sales	11,469	7	5,693	5	2,234	-1	649	14	2,893	16

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

* Over 500%

4. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025
Ocrevus	1,778	6	1,728	10	1,684	6	1,820	16	1,692	6
Hemlibra	1,165	11	1,256	22	1,105	4	1,228	8	1,190	13
Vabysmo	1,018	18	1,049	19	996	4	1,039	7	1,024	13
Tecentriq	870	0	863	-1	883	4	950	8	811	4
Xolair	645	26	800	41	781	34	849	26	708	26
Phesgo	593	52	604	57	630	51	614	34	686	27
Perjeta	840	-10	773	-14	703	-14	652	-13	672	-11
Actemra/RoActemra	619	-1	660	8	614	-2	577	-10	534	-4
Evrysdi	420	18	449	-1	424	10	464	26	464	19
Kadcyla	506	5	531	12	494	7	494	6	439	-4
Polivy	358	42	372	51	371	30	369	31	407	26
Alecensa	397	11	405	6	388	8	372	1	401	12
MabThera/Rituxan	298	-16	332	1	303	3	318	-3	292	10
Activase/TNKase	297	-2	253	-7	283	1	274	-2	255	-2
Gazyva	249	15	241	12	238	13	258	15	247	10
Herceptin	292	-20	268	-23	257	-15	211	-29	234	-12
Avastin	274	-15	248	-19	241	-11	210	-21	224	-9
CellCept	98	4	98	1	96	18	93	-16	99	10
Enspryng	83	27	94	27	92	25	95	17	96	31
Columvi	60	138	63	58	79	71	86	64	95	77

5. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

CHF millions	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025
Ocrevus	1,247	3	1,215	8	1,151	1	1,261	17	1,117	3
Hemlibra	610	0	714	21	617	-1	724	6	613	15
Vabysmo	718	7	732	10	689	-4	718	-1	652	4
Tecentriq	411	-8	408	-4	403	2	418	4	378	6
Xolair	645	26	800	41	781	34	849	26	708	26
Phesgo	179	38	169	40	175	29	185	22	159	2
Perjeta	342	-3	335	4	291	-6	300	4	263	-12
Actemra/RoActemra	294	3	325	11	307	-6	280	-19	248	-3
Evrysdi	160	15	149	10	159	18	144	0	160	15
Kadcyla	201	5	195	9	181	2	191	10	156	-11
Polivy	156	30	171	34	170	18	191	32	171	26
Alecensa	130	21	146	19	144	15	145	4	105	-7
MabThera/Rituxan	181	-14	206	2	188	5	219	5	183	16
Activase/TNKase	285	-2	242	-5	270	1	259	-2	244	-2
Gazyva	131	27	122	14	123	14	143	20	115	1
Herceptin	60	-12	61	-8	54	-6	50	-14	44	-16
Avastin	80	-21	76	-18	69	-16	74	-14	59	-15
CellCept	5	-5	4	-26	5	3	7	10	4	-5
Enspryng	21	11	25	20	25	9	26	1	22	20
Columvi	37	124	41	88	47	90	53	70	43	35

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025
Ocrevus	344	11	362	14	354	12	391	14	363	9
Hemlibra	247	7	246	7	247	14	262	12	252	5
Vabysmo	197	42	181	25	178	9	185	13	190	0
Tecentriq	220	5	214	1	216	0	228	7	202	-6
Xolair	-	-	-	-	-	-	-	-	-	-
Phesgo	199	18	202	13	201	9	210	9	206	7
Perjeta	144	-16	138	-15	136	-14	134	-7	119	-15
Actemra/RoActemra	152	-19	156	-7	142	-1	138	-7	124	-16
Evrysdi	145	6	147	3	158	7	166	21	159	13
Kadcyla	135	-7	131	-5	130	-5	136	0	123	-6
Polivy	94	74	66	119	68	21	62	26	63	-32
Alecensa	68	-6	65	-7	64	-10	65	-3	63	-5
MabThera/Rituxan	35	-10	35	-6	34	13	36	-13	31	-8
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Gazyva	60	-3	61	4	62	1	62	5	57	-2
Herceptin	77	0	73	-2	73	2	68	-9	69	-7
Avastin	14	-33	12	-46	28	47	16	-22	14	3
CellCept	34	7	31	17	32	49	34	-19	28	-14
Enspryng	10	44	9	36	11	37	10	36	11	20
Columvi	12	92	13	70	18	51	19	65	21	84

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International

CHF millions	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025
Ocrevus	187	16	151	23	179	35	168	11	212	24
Hemlibra	226	72	195	60	149	9	140	18	244	14
Vabysmo	71	101	98	130	94	111	95	118	145	126
Tecentriq	158	21	148	7	176	17	217	25	162	14
Xolair	-	-	-	-	-	-	-	-	-	-
Phesgo	175	142	183	230	205	213	170	122	279	78
Perjeta	336	-9	281	-27	259	-21	203	-30	278	-9
Actemra/RoActemra	102	26	98	25	87	7	79	6	96	5
Evrysdi	95	56	127	-15	85	4	132	116	127	40
Kadcyla	149	21	181	33	160	28	144	9	141	5
Polivy	64	80	80	94	79	105	62	67	127	120
Alecensa	150	12	143	2	129	8	109	-3	190	39
MabThera/Rituxan	79	-23	87	2	77	-5	60	-22	75	6
Activase/TNKase	12	-9	11	-37	13	18	15	-4	11	-4
Gazyva	50	11	49	18	45	24	43	8	66	45
Herceptin	153	-29	132	-34	128	-25	92	-42	120	-14
Avastin	144	-3	120	-15	109	-13	86	-26	130	-1
CellCept	47	-4	51	-8	49	7	42	-18	58	37
Enspryng	15	171	19	40	14	60	15	32	28	93
Columvi	11	345	9	-16	14	48	14	45	31	204

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others